Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
criver.com

See what CB Insights has to offer

Founded Year

1947

Stage

IPO | IPO

Date of IPO

3/7/2001

Market Cap

16.98B

Stock Price

417.22

About Charles River Laboratories

Charles River Laboratories (NYSE: CRL) provides products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. The company's dedicated employees are focused on helping clients improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them.

Charles River Laboratories Headquarter Location

251 Ballardvale Street

Wilmington, Massachusetts, 1887,

United States

781-222-6000

Latest Charles River Laboratories News

Libra Therapeutics Appoints Philip Lambert, Ph.D., as Chief Scientific Officer

Oct 19, 2021

October 19, 2021 08:00 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )-- Libra Therapeutics, Inc. today announced the appointment of Philip Lambert, Ph.D., as the company’s first chief scientific officer. With more than 25 years of drug discovery and development expertise in the areas of neuroscience, metabolic, inflammatory, and orphan diseases and a neuroscientist by training, Dr. Lambert will lead Libra’s development of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Dr. Lambert joins Libra from CENTOGENE, where he was Chief Scientific Officer and led the company’s drug discovery operation. “We are excited to welcome Phil, who has advanced into clinical trials more than 20 small and large molecule therapeutics for multiple diseases,” said Isaac Veinbergs, Ph.D., President and CEO of Libra Therapeutics. “In addition to his drug discovery expertise, he is a trained neuroscientist and a serial entrepreneur who has built programs and teams from the ground up. Phil’s experience will be key as we seek to develop novel therapies to deliver meaningful improvements in patient outcomes across a wide range of neurodegenerative diseases.” “I’m impressed with Libra’s therapeutic platform that’s uniquely positioned to discover and develop novel small molecules designed to increase critical cellular processes to more rapidly clear and attenuate the production of neurotoxic proteins,” said Dr. Lambert. “I look forward to working with the team and translating the company’s breakthrough science into new therapies with the potential to slow or prevent neurodegeneration and disease progression.” Dr. Lambert has a unique background as a well published researcher, serial entrepreneur, and a leader who has held senior positions in academia, biotechnology, non-profit, large pharmaceutical, and contract research organizations. As a serial entrepreneur, he was a member of the management team that conducted the due diligence and sale of Sirtris to GSK. He also cofounded, effectively grew, and sold VivoPath, a contract research organization to Charles River Laboratories. Dr. Lambert has held positions at CENTOGENE, Life Biosciences, Charles River Laboratories, Sirtris Pharmaceuticals, Forum Pharmaceuticals, ALS Therapy Development Institute, Regeneron Pharmaceuticals, GSK, and Parke Davis. He received his Ph.D. in neuroendocrinology from Imperial College London and was a faculty member in the Department of Psychiatry at Emory University School of Medicine. About Libra Therapeutics Libra Therapeutics is a biotechnology company focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. The company is advancing three distinct and novel preclinical small molecule programs designed to increase autophagy and decrease production of neurotoxic protein aggregates. Libra Therapeutics was founded to capitalize on proprietary technologies and therapeutic assets from Axxam, a leading discovery research company. The company is based in San Diego. To connect with the company, visit www.libratherapeutics.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Charles River Laboratories

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Charles River Laboratories is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Charles River Laboratories Patents

Charles River Laboratories has filed 52 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Graphical projections
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/10/2018

9/21/2021

Monoclonal antibodies, Immunology, Immune system, Clusters of differentiation, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/10/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/21/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoclonal antibodies, Immunology, Immune system, Clusters of differentiation, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Charles River Laboratories Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Charles River Laboratories Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.